PreveCeutical Medical Inc. provided a further update on its dual gene therapy research program (the "Dual Gene Therapy Program"), an important and fundamental aspect of which involves the design, synthesis and screening of small interfering RNA ("siRNA") constructs in downregulating the gene of interest that the Company is targeting in connection with its research on curative and prevention therapies for type 2 diabetes and obesity. This was an important development, confirming that the proprietary chemistry applied during the development of the Smart-siRNAs did not compromise the efficacy and specificity of the panel of siRNA constructs. PreveCeutical confirmed that a further, potent novel siRNA construct has been added to the panel. This construct has been engineered into a Smart-siRNA form and its screening is anticipated to be completed in the near future. The Smart-siRNA constructs have been designed with the final phase of the Dual Gene Therapy Program in mind, where the construct's biostability will be essential for assessment in preclinical (mice) models of type 2 diabetes and obesity.